Suzanne K.
- Country
- The Netherlands
- Department
- Department of Medical Oncology
Research Overview
- Randomized Phase II/III Study of Cabozantinib Maintenance Versus Best Supportive Care in Osteosarcoma Patients After First‑Line Chemotherapy (FOSTER‑CabOS)
- Randomized Controlled Trial of Chemotherapy Regimens Including Gemcitabine, Lenvatinib, and Temozolomide for Recurrent and Primary Refractory Ewing Sarcoma
Data & Insights
Has run more than one trial at 24 of 95 partner sites.
Specializations
Oncology Focus
This investigator specializes in the treatment of Ewing Sarcoma, with particular emphasis on challenging cases including recurrent disease and primary refractory conditions.
- Bone Cancer Treatment
- Refractory Disease Management
- Pediatric Oncology
Key interests include systemic therapeutic approaches and response assessment in rare bone cancers.
Therapeutic Expertise
The investigator focuses on developing and evaluating systemic anti-cancer therapy regimens, particularly in complex cases where standard treatments have proven insufficient.
- Treatment Efficacy Assessment
- Imaging Response Evaluation
- Survival Analysis
Special attention is given to therapeutic efficacy and patient tolerance in advanced sarcoma cases.
Clinical Assessment
Areas of expertise include comprehensive evaluation of treatment toxicity and patient acceptability in challenging oncological conditions.
- Treatment Safety Monitoring
- Patient Response Assessment
- Therapeutic Optimization
Focus includes balancing treatment effectiveness with patient tolerance and quality of life considerations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.